Print this page
-
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).
Protocol: 111803Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas.
Protocol: 112409Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
An open-label, single-arm, multicenter, phase 3 study to assess pharmacokinetics, safety and tolerability of iptacopan in pediatric PNH patients 2 to <18 years of age
Protocol: 112501Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: -
Collection of Pediatric and Adult Research Specimens for CNS Malignancies.
Protocol: 112503Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Any Site -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT).
Protocol: 112504Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB).
Protocol: 112505Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lung -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Novel Immune Checkpoint Expression on Circulating Tumor Cells of Sarcomas.
Protocol: 112103Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis.
Protocol: 112506Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Other Hematopoietic -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney